BRAF and neoplasm: On the other hand, if a combination would work exclusively synergistic in a specific tumor cell population (e. g., BRAF-mutant cells) and not in other cells (i. e., BRAF-wild type, or non-malignant cells), this would amplify the specific effect of the inhibitors.